GeneCraft is pioneering the field of gene therapy for cancer patients with K-RAS mutation. Our pipeline is designed to unlock the next level of oncology by building on the most recent advances in gene therapy. GeneCraft’s lead program is focused on transforming the treatment paradigm in K-RAS mutated lung cancer by orchestrating gene driven, innate oncogene defense system.
RX001 is the first-in-class treatment for Pan K-RAS mutated lung cancer.
RX001 distinguishes abnormal K-RAS mutated cancer cells from normal cells and selectively induces the death of the cancer cells.
With its Ubi-AAV Platform, GeneCraft is able to craft gene contents into new gene therapeutics.